Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4010 Plus Nivolumab in Previously Treated Metastatic NSCLC
NCT02823990Phase 2Completed
- Start
- Dec 2016
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of TG4010 in non-small cell lung cancer (NSCLC). Started Dec 2016; status: completed.
02
Drugs
TG4010
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02823990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823990.